dm+d

703798002

New Medicines

IclusigPhiladelphia chromosome positive acute lymphoblastic leukaemia (ALL) - first-line

Information

Iclusig
Licence extension / variation
Incyte
Takeda Oncology

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

BCR-ABL kinase inhibitor including T315I mutations
ALL is the most common cancer in children. Global incidence is about 3 per 100,000 population, with about 3 out of 4 cases occurring in children aged under 6 years [1].
Philadelphia chromosome positive acute lymphoblastic leukaemia (ALL) - first-line
Oral